Like ovarian cancer, breast cancer can have genetic defects in HRR pathways, which results in HRD [1]. The most well-known HRR genes affected in breast cancer are BRCA1 and BRCA2. The role of defects in other HRR genes such as RAD51C, RAD51D, ATM, BARD1, PALB2 and BRIP1 is currently being characterised.
Further information on the clinical activity of PARP inhibitors in breast cancer can be found by clicking on each topic below.